Ash Stevens gets FDA nod for ixazomib production; Anderson appointed CMO at Symbiosis; Idera inks deal with GSK;

> The FDA has given Ash Stevens ($ASI) the go ahead to begin manufacturing the API ixazomib, an oral proteasome inhibitor used to treat multiple myeloma, at the company's Riverview, MI, facility. Story

> Symbiosis Pharmaceutical Services has appointed Joanne Anderson at its new business development director. Release

> Idera Pharmaceuticals ($IDRA) has entered into a $100 million collaboration and license agreement with GlaxoSmithKline ($GSK) to research, develop and commercialize for the treatment of renal disease. Story

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.